Background: Parkinson’s disease (PD) is a neurodegenerative disorder with growing prevalence, age-standardised death rates and disability. Recent expansions in cannabis legalization have revived interest in therapeutic applications of medical cannabis and its derivatives (MC) in PD. Our team previously conducted a systematic review and meta-analysis on the use of MC in PD patients to determine its effect on motor function and its safety profile.
